Maravai Lifesciences: Trilink Customer
Director at Beam Therapeutics
inpractise.com/articles/maravai-lifesciences-trilink-customer
Director at Beam Therapeutics
Interview Transcript
This is a snippet of the transcript, sign up to read more.
Could you talk about the cost of buying nucleotides from TriLink and building the cap yourself versus the cost of having the end product cap as what you purchase; if not in dollar terms, maybe proportionate terms, like the end cap costs X percent more than buying the nucleotides and building it yourself, or is it just not that simple to think in those terms?
It's not that simple because you have to navigate the IP space, and the ability to do that chemical synthesis and purification is a very high upfront investment, to have those capabilities established in-house. You can have a vessel with enzymatic reaction, but if you start going into the chemistry of that, that in itself has a whole layer of build out and upfront costs associated with those. Unless you're big pharma that has the capabilities, that's not something you can in-source, so to speak. Even then, you still have to navigate the IP space, so you can't simply build the same structure.
This is a snippet of the transcript, sign up to read more.
Related Content
Maravai LifeSciencies: Trilink Biotech
Principal Scientist at Moderna
Couche-Tard Unit Growth & Fuel Margin, ODFL, CCOI, MRVI, FEVR
Maravai LifeSciences: CleanCap, Competition, & mRNA Innovation
Former Executive at Maravai LifeSciences
Maravai LifeSciences: CleanCap vs. Enzymatic Capping
Former VP at Maravai LifeSciences
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.